Piotr Jan Wysocki

Summary

Affiliation: Medical University of Silesia
Country: Poland

Publications

  1. ncbi 3rd international symposium on genetic anticancer agents
    Piotr J Wysocki
    Department of Cancer Immunology, Chair of Oncology, USOMS, at GreatPoland Cancer Center, Garbary Street 15, 61 866 Poznan, Poland
    Expert Opin Biol Ther 2:565-8. 2002
  2. ncbi Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin
    Piotr J Wysocki
    Department of Chemotherapy, Greater Poland Cancer Center, University of Medical Sciences, Poznan, Poland
    Expert Rev Mol Diagn 10:509-19. 2010
  3. ncbi Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer
    P J Wysocki
    Department of Cancer Immunology, Chair of Medical Biotechnology, University of Medical Sciences at GreatPoland Cancer Center, ul Garbary 15, Poznan, Poland
    Cancer Gene Ther 17:465-75. 2010
  4. ncbi Targeted therapy of hepatocellular cancer
    Piotr Jan Wysocki
    University of Medical Sciences, Department of Chemotherapy, Greater Poland Cancer Center, ul Garbary 15, Poznan 61 866, Poland
    Expert Opin Investig Drugs 19:265-74. 2010
  5. ncbi mTOR in renal cell cancer: modulator of tumor biology and therapeutic target
    Piotr J Wysocki
    Chair of Medical Biotechnology, Department of Cancer Immunology, University of Medical Sciences, GreatPoland Cancer Center, ul Garbary 15, Poznan, 61 866, Poland
    Expert Rev Mol Diagn 9:231-41. 2009
  6. ncbi Cardiovascular complications associated with biological therapies for breast cancer
    P J Wysocki
    Medical Biotechnology University of Medical Sciences Department of Cancer Immunology, ul Garbary 15, 61 866 Poznan, Poznan, Poland
    Expert Opin Biol Ther 8:1551-9. 2008
  7. ncbi Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations
    Piotr J Wysocki
    Department of Cancer Immunology, University of Medical Sciences, Poznan, Poland
    Med Sci Monit 14:SC7-10. 2008
  8. ncbi Recent developments in renal cell cancer immunotherapy
    P J Wysocki
    Chair of Medical Biotechnology, University of Medical Sciences at GreatPoland Cancer Center, Department of Cancer Immunology, ul Garbary 15, 61 866 Poznan, Poland
    Expert Opin Biol Ther 7:727-37. 2007
  9. ncbi Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice
    Piotr J Wysocki
    Department of Cancer Immunology, University of Medical Sciences at GreatPoland Cancer Center, Poznan, Poland
    Clin Cancer Res 12:4095-102. 2006
  10. ncbi The 34th Annual Meeting of the German Society of Immunology with participation of the Polish Society of Experimental and Clinical Immunology
    P J Wysocki
    Department of Cancer Immunology, University of Medicine at GreatPoland Cancer Center, Garbary St 15, 61 866 Poznan, Poland
    Expert Opin Biol Ther 4:253-6. 2004

Collaborators

Detail Information

Publications22

  1. ncbi 3rd international symposium on genetic anticancer agents
    Piotr J Wysocki
    Department of Cancer Immunology, Chair of Oncology, USOMS, at GreatPoland Cancer Center, Garbary Street 15, 61 866 Poznan, Poland
    Expert Opin Biol Ther 2:565-8. 2002
    ..The educational session aroused a great interest from the participants. The meeting highlights from different scientific sessions are presented...
  2. ncbi Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin
    Piotr J Wysocki
    Department of Chemotherapy, Greater Poland Cancer Center, University of Medical Sciences, Poznan, Poland
    Expert Rev Mol Diagn 10:509-19. 2010
    ..Several currently ongoing Phase II and III clinical studies are evaluating the therapeutic efficacy of metformin in the treatment of early and advanced breast cancer patients...
  3. ncbi Gene-modified tumor vaccine secreting a designer cytokine Hyper-Interleukin-6 is an effective therapy in mice bearing orthotopic renal cell cancer
    P J Wysocki
    Department of Cancer Immunology, Chair of Medical Biotechnology, University of Medical Sciences at GreatPoland Cancer Center, ul Garbary 15, Poznan, Poland
    Cancer Gene Ther 17:465-75. 2010
    ..In the orthotopic RCC model, RENCA-H6 vaccine showed high therapeutic potential, which resulted from modulation of numerous immunological mechanisms...
  4. ncbi Targeted therapy of hepatocellular cancer
    Piotr Jan Wysocki
    University of Medical Sciences, Department of Chemotherapy, Greater Poland Cancer Center, ul Garbary 15, Poznan 61 866, Poland
    Expert Opin Investig Drugs 19:265-74. 2010
    ..However, identification of signaling pathways responsible for HCC growth and progression such as RAS/RAF/MEK/ERK or PI3K/AKT/mTOR has determined crucial molecular targets and led to development of novel promising targeted therapies...
  5. ncbi mTOR in renal cell cancer: modulator of tumor biology and therapeutic target
    Piotr J Wysocki
    Chair of Medical Biotechnology, Department of Cancer Immunology, University of Medical Sciences, GreatPoland Cancer Center, ul Garbary 15, Poznan, 61 866, Poland
    Expert Rev Mol Diagn 9:231-41. 2009
    ..Such clinical trials evaluating a combination of mTOR inhibitors with other targeted therapies are ongoing...
  6. ncbi Cardiovascular complications associated with biological therapies for breast cancer
    P J Wysocki
    Medical Biotechnology University of Medical Sciences Department of Cancer Immunology, ul Garbary 15, 61 866 Poznan, Poznan, Poland
    Expert Opin Biol Ther 8:1551-9. 2008
    ..In the case of targeted therapies mechanisms of cardiotoxicity and strategies to manage cardiovascular disorders have not been completely defined...
  7. ncbi Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations
    Piotr J Wysocki
    Department of Cancer Immunology, University of Medical Sciences, Poznan, Poland
    Med Sci Monit 14:SC7-10. 2008
    ..Therefore the frequency of BRCA1 mutations in a population of metastatic docetaxel-refractory patients was analyzed...
  8. ncbi Recent developments in renal cell cancer immunotherapy
    P J Wysocki
    Chair of Medical Biotechnology, University of Medical Sciences at GreatPoland Cancer Center, Department of Cancer Immunology, ul Garbary 15, 61 866 Poznan, Poland
    Expert Opin Biol Ther 7:727-37. 2007
    ....
  9. ncbi Captopril, an angiotensin-converting enzyme inhibitor, promotes growth of immunogenic tumors in mice
    Piotr J Wysocki
    Department of Cancer Immunology, University of Medical Sciences at GreatPoland Cancer Center, Poznan, Poland
    Clin Cancer Res 12:4095-102. 2006
    ..In our study, we wanted to evaluate the effect of captopril on growth of immunogenic tumors in immunocompetent animals...
  10. ncbi The 34th Annual Meeting of the German Society of Immunology with participation of the Polish Society of Experimental and Clinical Immunology
    P J Wysocki
    Department of Cancer Immunology, University of Medicine at GreatPoland Cancer Center, Garbary St 15, 61 866 Poznan, Poland
    Expert Opin Biol Ther 4:253-6. 2004
    ..However, several workshop presentations demonstrated novel approaches employing biological therapies. These lectures are the focus of these meeting highlights...
  11. ncbi Genetically modified dendritic cells--a new, promising cancer treatment strategy?
    P J Wysocki
    Department of Cancer Immunology, University School of Medical Sciences at GreatPoland Cancer Centre, Poznan, Poland
    Expert Opin Biol Ther 2:835-45. 2002
    ..In this article, methods used for genetic modification of DCs and anticancer vaccination strategies based on genetically modified DCs are reviewed...
  12. ncbi Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines
    Wiktoria Maria Suchorska
    University of Medical Science, Medical Biotechnology, Garbary 15, Poznan, 61 866, Poland
    Expert Opin Biol Ther 11:1555-67. 2011
    ..Hyper-IL-11 (H11) is a fusion protein comprising IL-11 and soluble IL-11 receptor directly targeting gp130. We evaluated efficacy of H11 as a molecular adjuvant in therapeutic whole tumor cell vaccine formulation...
  13. ncbi The 32nd Annual Meeting of German Society of Immunology. 26 - 29 September 2001
    Piotr J Wysocki
    Department of Cancer Immunology, Chair of Oncology, USOMS at Grat Poland Cancer Center, Poznan, Poland
    Expert Opin Biol Ther 2:111-4. 2002
    ..Here we present meeting highlights, which were mostly devoted to therapeutic aspects of immunology...
  14. ncbi Interleukin 12-based immunotherapy improves the antitumor effectiveness of a low-dose 5-Aza-2'-deoxycitidine treatment in L1210 leukemia and B16F10 melanoma models in mice
    Katarzyna Kozar
    Department of Immunology, Center of Biostructure, Medical University of Warsaw, 02-004 Warsaw, Poland
    Clin Cancer Res 9:3124-33. 2003
    ..CONCLUSIONS: This study provides the first evidence that antitumor effects of DAC can be strongly potentiated by IL-12 and could be beneficial in an effective low-dose-based antitumor therapy...
  15. ncbi Cancer immunotherapy using cells modified with cytokine genes
    Dariusz W Kowalczyk
    Department of Cancer Immunology, Great Poland Cancer Center, University of Medical Sciences, Pozna, Poland
    Acta Biochim Pol 50:613-24. 2003
    ..Clinical trials, including our own experience, employing the above strategies are discussed...
  16. ncbi Targeted therapy of renal cell cancer
    Piotr J Wysocki
    University of Medical Sciences, GreatPoland Cancer Center, Department of Cancer Immunology, ul Garbary 15, 61 866 Poznan
    Curr Opin Investig Drugs 9:570-5. 2008
    ....
  17. ncbi Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model
    Grzegorz W Basak
    Department of Immunology, Centre of Biostructure Research, Medical University of Warsaw, 02 097 Warsaw, Poland
    Oncol Rep 19:1173-9. 2008
    ..To our knowledge, this is the first report that shows the universal genetically-modified tumor cell vaccine-augmenting properties of IL-15. The cytokine can be useful as an adjuvant in cancer gene therapy in humans...
  18. ncbi Complete tumour regressions induced by vaccination with IL-12 gene-transduced tumour cells in combination with IL-15 in a melanoma model in mice
    Witold Lasek
    Department of Immunology, Centre of Biostructure, Medical University of Warsaw, Chałubińskiego 5, 02 004 Warsaw, Poland
    Cancer Immunol Immunother 53:363-72. 2004
    ....
  19. ncbi Human cancer gene therapy with cytokine gene-modified cells
    Piotr J Wysocki
    University of Medical Sciences at GreatPoland Cancer Center, Department of Cancer Immunology, ul. Garbary 15, 61-866 Poznan, Poland
    Expert Opin Biol Ther 4:1595-607. 2004
    ..This article reviews the present status and perspectives of clinical trials of cancer immunotherapies utilising cytokine gene-modified cells...
  20. ncbi CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice
    Tomasz Switaj
    Department of Immunology, Center of Biostructure, Medical University of Warsaw, Warsaw, Poland
    Clin Cancer Res 10:4165-75. 2004
    ....
  21. ncbi Expression of PiT1 and PiT2 retroviral receptors and transduction efficiency of tumor cells
    Piotr Grabarczyk
    Department of Cancer Immunology, K Marcinkowski University of Medical Sciences, GreatPoland Cancer Center, Poznan
    Acta Biochim Pol 49:333-9. 2002
    ..We demonstrated that, using different transduction strategies, the relatively inefficient, widely used retroviral vector systems could be significantly improved...
  22. ncbi [Gene modified tumor vaccines in therapy of malignant melanoma]
    Piotr J Wysocki
    , Wielkopolskie Centrum Onkologii w Poznaniu
    Otolaryngol Pol 56:147-53. 2002
    ..More than 25% of objective clinical responses and significant life extension were observed. The encouraging results formed a basis for design of a phase III prospective, randomized clinical study...